US FDA declines to approve Atara’s therapy for rare blood cancer

Jan 12 (Reuters) – The ‍U.S. Food and Drug ‌Administration ‌on Monday declined to approve ​Atara ‍Biotherapeutics’ ​cell therapy ​for ‍a rare form of ‍blood cancer, the company ‍said.

(Reporting ‍by ​Sneha ​S ⁠K ‌in Bengaluru; Editing by Sahal ⁠Muhammed)